Risk of Poor Glycemic Control in Tamsulosin Versus Finasteride Users with Type 2 Diabetes Mellitus

This study examined the risk of poor glycemic control in men with type 2 diabetes using finasteride or tamsulosin for benign prostatic hyperplasia, involving 1,259 finasteride users and 580 tamsulosin users in New Zealand. Over a median follow-up of 2.4 years for finasteride users and 1.6 years for tamsulosin users, the incidence rates of poor glycemic control were 564 per 10,000 person-years for tamsulosin users and 409 per 10,000 person-years for finasteride users. After adjusting for baseline covariates, the study found no significant difference in the risk of poor glycemic control between the two groups, with a weighted hazard ratio of 1.27. Sensitivity analyses confirmed these findings, indicating that long-term use of either medication does not differentially impact glycemic control in this population. The study suggests further research with a larger sample size and longer follow-up is needed.